Is abiraterone combined with bicalutamide appropriate for metastatic prostate cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No, abiraterone plus bicalutamide is not appropriate for metastatic prostate cancer

The combination of abiraterone and bicalutamide should not be used together for metastatic prostate cancer. This combination has not been studied and is not supported by any guideline or evidence.

The Correct Treatment Approach

For Metastatic Castration-Sensitive (Hormone-Naïve) Prostate Cancer

Abiraterone should be combined with ADT (androgen deprivation therapy) plus prednisone/prednisolone—NOT with bicalutamide 1, 2, 1.

The FDA-approved and guideline-recommended regimen is:

  • Abiraterone 1,000 mg once daily
  • Plus prednisone 5 mg twice daily (or prednisolone)
  • Plus ADT (LHRH agonist, LHRH antagonist, or orchiectomy)

This triple combination is indicated for 3:

  • High-risk metastatic hormone-sensitive disease (LATITUDE criteria: ≥2 of Gleason ≥8, ≥3 bone metastases, visceral metastases) 1, 2
  • Lower-risk metastatic disease may also be offered this combination 2

Why Not Bicalutamide with Abiraterone?

Bicalutamide is a first-generation antiandrogen that serves as an alternative to abiraterone, not a complement to it 4. The evidence clearly shows:

  • Abiraterone is superior to bicalutamide when each is combined with ADT 5, 6, 7, 8
  • Studies comparing these agents show abiraterone significantly prolongs time to castration resistance and improves survival outcomes compared to bicalutamide plus ADT 6, 7
  • Using both together has no evidence base and is not recommended 1, 2, 1

The Standard Treatment Options for Metastatic Disease

For newly diagnosed metastatic castration-sensitive prostate cancer, you have four separate standards of care 2:

  1. ADT + abiraterone + prednisone
  2. ADT + enzalutamide
  3. ADT + apalutamide
  4. ADT + docetaxel (particularly for high-volume disease)

These cannot be combined with each other or used in any particular sequence without evidence 1, 2.

Common Pitfall to Avoid

The critical error here is thinking that adding bicalutamide to abiraterone provides additional androgen blockade benefit. In reality:

  • Abiraterone blocks androgen synthesis (CYP17 inhibitor)
  • Bicalutamide blocks the androgen receptor
  • However, abiraterone already requires concurrent ADT (which achieves castrate testosterone levels), making bicalutamide redundant and unsupported
  • The steroid (prednisone/prednisolone) given with abiraterone is to prevent mineralocorticoid excess, not for additional cancer control 4

For Metastatic Castration-Resistant Prostate Cancer

If the disease has already progressed to castration-resistant state, abiraterone is still used with prednisone plus continued ADT—again, not with bicalutamide 9, 10, 3.

Bottom line: Use abiraterone with ADT and prednisone/prednisolone as a complete regimen. Do not add bicalutamide to this combination.

References

Guideline

prostate cancer, version 2.2019, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2019

Guideline

prostate cancer, version 3.2026, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.